Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of Novosis Goserelin 10.8 mg vs Zoladex 10.8 mg and Novosis Goserelin 3.6 mg in advanced prostate cancer
2006-004587-30Phase 3Completed
- Sponsor
- Novosis
- Start
- Aug 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of goserelin in prostate cancer (PCa) (3 arms), sponsored by Novosis. Primary endpoints: Non-inferiority of Novosis Goserelin 10.8 mg vs Zoladex 10.8 mg and Comparability of Novosis Goserelin 3.6 mg vs Novosis Goserelin 10.8 mg. Started Aug 2006; status: completed.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-004587-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004587-30.